Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I know we need news, the question is when will we get the news we need?
RXi Pharmaceuticals to Present at the 8th Annual Biotech Showcase 2016
http://finance.yahoo.com/news/rxi-pharmaceuticals-present-8th-annual-120200513.html
Just another Pump PR to sell more shares on open market with. They waited until 11:00 a.m to release this instead of before the market opened, and its really not that news-worthy as everything the CEO has stated they would do has never come true.
AMBS can't uplist unless they can get the share price over $2 , and unless they establish a partnership with a pharma company I don't see that happening.
Partnership news coming in my opinion. Long overdue for a company like RXII targeting scarring of skin, scarring of eyes, cosmeceuticals, macular degeneration, cancer etc.
Yup they pumped it up so they could dump shares at a higher price for conversion. Why would they dump shares at .40 cents when they could pump it up to a dollar and then sell for more money? It was a classic pump and dump scheme.
Quite possible we could start to see some accumulation mode
That's too much even for a CEO of a small cap biotechnology company. Especially in small biotech stocks where all the money matters because there is no revenue stream. He should reduce that down to maybe $200,000 but that's just crazy, $658,000 really?
Didn't Jason Napodano give AMBS a price target of $50 per share after the reverse split? maybe that's why he was let go by Zacks investment research.
I doubt he would openly admit it. Asking him won't do any good as he will deny it.
Dr. Lowe saw the writing on the wall he probably didn't want this reputation tarnished because of this disaster.
The company is only in phase 2a. The company will have to run a phase 2b trial first before phase 3. you are jumping the gun here. Phase 2b is next first.
Everyone knows how the stock market game is played right?
Adam Feurstein writes negative articles intentionally to bring the share price down. He gets paid from big hedge funds to do this in a coordinated effort. Notice how he says that he has no positions in all the articles he writes? That's true because he doesn't have the position, the hedge funds that are paying him do.
Further evidence is that hedge funds are not required to display what stocks they are short in SEC filings like their long positions. Therefore there is no way of knowing who is short what stock?
Then what many don't know is they go long after they have brought it down, going long.
Example of what you wont' find but what I remember about Arena Pharmaceuticals (ARNA)
Adam wrote article two weeks before FDA decision for approval
"Why Arena Won't receive FDA approval"
Then one day before the FDA panel this was the article
"Why Arena will receive FDA approval"
If you look for the first one you won't find it. The stock market is a game and you have to know how to play it to win.
You should know by now lol that management always files quarterly reports late. They are never one time, just another instance of terrible management
The board of directors aren't doing their job. Gerald should have been gone long time ago. Now toxic financing along with frustrated shareholders = disaster in the making. This is headed lower over the next few days. If you want your cheap shares you will get your opportunity soon.
read the second quote all the way on the bottom with this statement
"The Georgetown Assays are also in the mix and you can bet that the newly assembled teams will be eager to further develop these assays and complete the acquisition"
Didn't GC state in his most recent blog that Amarantus chose not to go with the Georgetown option agreement?
"We are also continuing to evaluate the next set of studies to further enhance LymPro’s value by combining datasets with other markers, such as PET imaging. We have come to the decision that we will be focusing on the assets currently in the company, and will forego the option agreement with Georgetown University."
This link from chairman's blog
http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/improving-healthcare-for-patients-and-their-families-believing-in-our-vision-through-ups-and-downs/
Not really. Will probably update on when Samcyrpone phase 2 trial in Warts will begin. Supposed to start this quarter -- 4th quarter 2015.
Other than that we need CEO Geert to deliver on a partnership as all other good news from the company hasn't done much against short sellers.
Not really. Will probably update on when Samcyrpone phase 2 trial in Warts will begin. Supposed to start this quarter -- 4th quarter 2015.
Other than that we need CEO Geert to deliver on a partnership as all other good news from the company hasn't done much against short sellers.
It was done so the outstanding shares could go back to low again. You caught on fast. This way they could get to one billion shares all over again.
Not to mention that they should have advanced MANF for Parkinson's or Alzheimer's like they have been saying. they are going with retinitis pigmentosa instead
Article I wrote for Anavex on Phase 2a results. This is how I as a real biotech analyst works by talking about the endpoints and science.
http://www.talkmarkets.com/content/news/anavex-announces-positive-phase-2a-results-in-patients-with-alzheimers?post=77602
Those analysts or websites always put a disclaimer. They have to. In essence they are saying this is " our opinion" on the stock but investors should do their own due diligence -- meaning research.
You can't really hold one guy accountable, plus working under zacks they probably have on their website a legal disclaimer for protecting themselves from what you speak of. All financial news websites have it.
JP I agree with you. They needed a definitive plan to move forward the CEO honestly doesn't know what he is doing. Just trying to learn the ropes while he flushes cash down the drain and plays with shareholders money.
Every time investors get an update its something new. Like the transact part about diagnostics, now they say they are taking it one step further etc.
There is just no foundation for a well executed plan. Plus adding the ESS in there is just weird IMO. AMBS is a neurology company, but ESS is a dermatological compound. IMO the company is now trying to throw hail marys in hopes of landing a blow like in your first picture.
Read the last sentence carefully. They are saying that Eltoprazine and ESS can be spun out as a separate standalone company. its in plain english.
I read the chairman's blog to see and its not good.
1. Now they are thinking about spinning out Eltoprazine or ESS as a standalone company since each has 3 indications it could target.
Terrible Idea you breakdown your pipeline. What value will be if you move assets out of the pipeline to a company spin out.
2. NASDAQ listing is a fail " However, after completing a capital restructuring in the second quarter, conditions in the market for our common shares rapidly deteriorated in the third quarter, causing the Company to fall out of compliance with initial NASDAQ listing standards. As we move forward, a significantly reduced share float due to the capital restructuring combined with an ultra-low valuation compared to peers for each asset in our portfolio, put the company in a reasonable position where value appreciation of our common stock could potentially occur and allow us to organically regain compliance with initial NASDAQ listing standards. An important step towards a sustainable financial future has been the reduction in our ongoing burn to under $500k per month as we focus our resources primarily on ESS."
How about they should have waited to do the reverse split first until they could maintain their share price. Utter failure there as well, now NASDAQ listing is a Pipe Dream
3. In terms of Eltoprazine they are still trying to figure out the best path, and which indication to go after first
Well isn't that nice company still doesn't know which one will get to market faster. Another fail
4. In terms of Lympro company is not choosing to move forward with the opotion Agreement from Georgetown University. Read this
"With data coming up on the use of LymPro in Chronic Traumatic Encephalopathy that we recently completely enrollment for in Boston University’s DETECT study, we believe we have sufficient critical mass to make a very successful business from our current diagnostics portfolio and are now focused on the CLIA launch plans for these products. We remain on track to transact on the diagnostics division in the fourth quarter and will provide updates on this as progress is made. The Company is looking forward to the JP Morgan Healthcare Conference the week of January 11, 2016 as a key time to potentially make public announcements of definitive agreements."
More mumbo jumbo promises to get clia Launch for Lympro which still hasn't materialized.
Well there is your recap you wanted! I don't think this company is a good investment. management is clueless and they don't know what their plan is to be quite honest.
That's a statement I can agree with. Didn't he say Chairman blog would be out this week?
It's being heavily shorted just keep adding, average down, or hold. All it takes is for one partnership news for this to rocket.
More news - Edison Research firm in London initiated coverage of Rxi with a price target of $1.40 in the near-term.
http://www.prnewswire.com/news-releases/edison-initiates-coverage-on-rxi-pharmaceuticals-540752261.html
RXi Pharmaceuticals Announces the Initiation of a Phase 1/2 Trial in Ophthalmology with RXI-109 for Retinal Scarring
http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-initiation-phase-120200657.html
this extension for RXII is good news, expect institutions to buy in now. Also expect partnerships to bring the PPS above $1 soon.
Likely we will see an extension tomorrow. Otherwise we would have seen an SEC filing from the company today. I'm betting on extension tomorrow and possibly other news as well.
Actually Jason Napodano no longer works for Zacks from what I remember. He says that he quit, IMO its quite possible he got the boot.
I think the company should get the extension. We shall See
I can't argue you with you on that statement. For instance what's up with posting that ESS news for 13 year followup. Old news rehashed to boost share price. Anyways AMBS shouldn't be focusing on a dermatology indication ESS. Should be focusing on its neorology pipeline.
Of course not. IND's only take on average 6 months maybe 1 year in some instances but that's stretching it. This has been in IND status for 2 years or more. They aren't getting anything done with the FDA. Doesn't take this long for one IND.
I told people what this company needs to do to fix itself.
1. Bring MANF into clinic for parkinsons/Alzheimer's forget Retinitis pigmentosa
2. Remove ESS. This company is a neurology company. ESS is dermatological indication. company should stick with what it's good at in neuro space
3. Reduce costs substantially. Too much stuff in the pipeline that is fluff and adds no value, and takes up a lot of money. Cutdown the pipeline to only few programs. Advance those straight to phase 3 for value creation
4. Get rid of the CEO. Unfortunately as long as Gerald's father is on the BOD that wont' happen.
Until the majority of the stuff listed above happens this will continue to fall
Well its called "Nepotism" where Gerald's father will never remove his own son from the company. Just not gonna happen.
But they expanded the pipeline too much. Their a neurological company, therefore their focus should be on Alzheimer's/Parkinsons. Look at their burn rate now, they are burning $2 to $3 million per month. Other small cap biotechs burn the same amount in 3 months instead of 1 month.
I'm all for companies expanding their pipelines but they had no money to be expanding to other areas. Instead just focus on the main ones MANF for Parkinsons/Alzheimers, Elto, and Lympro. Matter of fact why aren't they advancing Lympro? Forget ESS that is a long shot and that was owned by another previous company who didn't get it to market anyways.
You are correct. Here is what the CEO should have done. Forget about ESS that's not the company's focus. Focus on the main pipeline keep costs down as they don't have money.
Burn money only on main programs like Lympro, Eltoprazine, MANF.
Get rid of of this other junk they added like MS test, ESS, etc.
Company needs to manage cash burn more appropriately. First of all ESS is not even part of their company its a skin substitute -- that falls under dermatology.
This company should work on what it was focused to do Alzheimer's/Parkinson's.
Advance MANF for Alzheimer's/Parkinsons - Instead they are focusing on a rare eye disease retinitis pigmentosa. terrible management decisions is driving this down the hole.
Just watching from the sidelines, good thing I don't own this. I feel really bad for shareholders that have lost a lot of money here to the CEO.